Opinion|Videos|March 26, 2025
Emerging Treatment Landscape and Future Outlook for Friedreich Ataxia
Author(s)David R. Lynch, MD, PhD
An expert discusses how vatiquinone targets Friedreich ataxia in patients with balance issues by inhibiting 15-lipoxygenase to reduce oxidative stress. Novel dual-route gene therapy combines systemic IV and targeted dentate nuclei delivery, addressing both central and peripheral manifestations while potentially offering disease-modifying benefits.
Advertisement
Video content above is prompted by the following:
- A new drug application has been submitted for vatiquinone, an emerging 15-lipoxygenase inhibitor drug, for its treatment effects on upright stability in patients with Friedreich ataxia.
- Please discuss the targeted patient population, quality-of-life data, and safety profile for vatiquinone.
- The FDA also recently provided clearance for a first-in-industry dual route of administration of gene therapy via systemic IV infusion and direct intradentate nucleiinfusion.
- Please briefly explain the rationale of this dual-route administration.
- What are the potential implications of gene therapy, both as monotherapy and in combination with other therapies, in the treatment of Friedreich ataxia in the future?
- Please share your final thoughts on the treatment of Friedreich ataxia and the future outlook for its treatment.
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.
At a NeurologyLive Clinical Forum in Philadelphia, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.
The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.
GV101 receives FDA fast track designation for the treatment of Friedreich ataxia, with a phase 2 trial planned to begin enrollment in late 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
3
Headlining Current Advances and Challenges in Multiple Sclerosis Care
4
New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients
5